As per reports, Johnson & Johnson (JNJ) reported mixed quarter results with $28.4 billion in sales. Adjusted profit of $2.13 per share was reported a little higher than $2.12 expected and driven by high Covid vaccine sales. On a year-over-year basis, sales grew more than 10% and earnings advanced almost 15%. The medical devices segment generated $27.06 billion in sales, posting the best growth among the company’s business segments, at nearly 18%. Drug sales rose more than 14% to $52.08 billion. The consumer health business brought in $14.64 billion in sales, a 4.1% increase.
For the year 2022, the pharmaceutical giant expects to earn $10.40-$10.60 per share on $98.9 billion to $100.4 billion in sales. Johnson & Johnson expects sales of its single-shot vaccine expected to reach $3 billion to $3.5 billion, amid the surging omicron variant cases across the U.S. and world.
Dow 30 component Johnson & Johnson (JNJ) is a worldwide healthcare-focused company that embraces research and science so that it can provide customers with innovative ideas, products, and services. To learn more about Johnson & Johnson (JNJ) and to continue to track its progress visit the Vista Partners Johnson & Johnson Coverage Page.
If you liked this story please consider, visiting the Atossa Therapeutics (ATOS) dedicated page at Vista Partners to learn about the Seattle-based biotech firm’s work towards finding therapeutic treatments for Breast Cancer and the Coronavirus.
Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.
Stay Informed! Stay Competitive! Please join us at Vista Partners, receive our FREE email updates throughout the week, and view our exclusive content and research.